Global Lung Markers Market Size Worth US$665.6 Million By 2027,

Lung Markers Market

Lung Markers Market

According to IMARC Group’s latest report titled “Lung Marker Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, the global lung marker market size reached US$349.3 million in 2021. The IMARC Group expects the market to reach $665.6 million by 2027, at a growth rate (CAGR) of 11.95% over the period 2022-2027.

Lung markers are substances produced by tumor cells that serve to localize the lungs. They are produced in the body in response to cancer and are found in patients’ urine, blood and stools. They are used during pulmonary intervention procedures to provide information about the type and status of cancer. They also help diagnose, predict, and monitor the tumor to understand the type of therapy needed to treat the condition. In addition, they are used in numerous hospitals and other healthcare facilities to diagnose and treat pleural effusions and mesothelioma.

We regularly track the direct impact of COVID-19 on the market as well as the indirect impact of related industries. These observations are integrated into the report.

Request a free sample report (exclusive offer for this report): https://www.imarcgroup.com/lung-marker-market/requestsample

Market Trends:

The global market is primarily determined by the increasing prevalence of lung cancer and the associated high mortality rates. This has prompted the major players to invest heavily in research and development (R&D) to introduce an effective cure. Since lung markers are an indispensable part of lung localization, there has been a significant increase in their demand. Added to this is the increased occurrence of respiratory diseases due to deteriorating air quality, unhealthy lifestyles and high smoking rates in the general public. In addition, the growing global geriatric population is vulnerable to acute respiratory diseases, driving demand for lung markers. The governments of several countries also provide numerous health services for the early detection and pre-treatment of several chronic diseases, such as: B. lung cancer, which acts as another important growth factor.

READ :  How employers will control high health care costs in 2023

Ask the analyst for an instant discount and download the full report with TOC and list of figures: https://www.imarcgroup.com/lung-marker-market

Competitive landscape with key players:

• Abbott Laboratories
• Thermo Fisher Scientific Inc
• Agilent Technologies, Inc
• Beckman Coulter, Inc
• Fujirebio Europe NV
• Hologic, Inc
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers
• BioSpace, Inc

Key segmentation:

Separation by cancer type:

• Non-small cell lung cancer (NSCLC)
• Small cell lung cancer (SCLC)

Breakdown by marker type:

• EGFR
• EML4-ALK
• KRAS
• BRAF
• Other

Separation by end users:

• Hospitals
• Diagnostic Laboratories
• Other

Breakdown by region:

• North America (United States, Canada)
• Europe (Germany, France, UK, Italy, Spain, others)
• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, others)
• Latin America (Brazil, Mexico, others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key highlights of the report:

• Market performance (2016-2021)
• Market Outlook (2022-2027)
• Porter’s Five Forces Analysis
• Market drivers and success factors
• SWOT analysis
• Value chain
• Comprehensive mapping of the competitive landscape

Note: If you require specific information that is not currently included in the scope of the report, we can provide it to you as part of the customization.

Contact us:

IMARC Group
30 N Gould Street, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: [email protected]
Tel: (D) +91 120 433 0800
America:- +1 631 791 1145 | Africa and Europe:- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

About us:

IMARC Group is a leading market research company providing management strategies and market research worldwide. We partner with clients across sectors and geographies to identify their most valuable opportunities, address their most critical challenges, and transform their businesses.

READ :  Important things to know about health savings accounts as you approach retirement

IMARC’s information products cover key market, scientific, economic and technological developments for executives in pharmaceutical, industrial and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food & beverage, travel & tourism, nanotechnology and advanced processing methods are at the forefront of the company’s expertise.

This version was published on openPR.

Leave a Reply

Your email address will not be published. Required fields are marked *